commitment
to biosimiliars

Every biosimilar we add to our portfolio
provides more patients in more
countries with the treatment they need.
We are committed to continuing to
invest in biosimilars.

Diabetes &
Metabolics

Oncology

Dermatology

Immunology

Ophthalmology

growing portfolio

We offer one of the industry's largest and most diverse global biosimilars franchises focused on the areas of oncology, immunology, endocrinology, ophthalmology and dermatology.

At present, Health Canada has approved 27 biosimilars for use in Canada, within the product classes of human growth hormone, granulocyte colony-stimulating factor (G-CSF), insulin, monoclonal antibodies and tumour necrosis factor (TNF)-inhibitor.1


industry-wide savings

  • Biosimilars play an important role in our commitment by offering additional therapeutic options to more expensive biologics.
  • Increasing uptake of biosimilars in Canada is projected to generate potential savings of as high as CA $447 million by 2023.2

Reference:

  1. GaBIonline. Biosimilars approved in Canada. Generics and biosimilar initiative. Available at: https://www.gabionline.net/biosimilars/general/biosimilars-approved-in-canada. Accessed on: 6 September 2021.
  2. GaBIonline. Cost savings from biosimilars in Canada: Actual and projected. Generics and biosimilar initiative. Available at: https://gabionline.net/reports/Cost-savings-from-biosimilars-in-Canada-actual-and-projected. Accessed on: 6 September 2021.